1937 related articles for article (PubMed ID: 30360816)
1. Nanoparticle Delivery of TWIST Small Interfering RNA and Anticancer Drugs: A Therapeutic Approach for Combating Cancer.
Glackin CA
Enzymes; 2018; 44():83-101. PubMed ID: 30360816
[TBL] [Abstract][Full Text] [Related]
2. Targeting the Twist and Wnt signaling pathways in metastatic breast cancer.
Glackin CA
Maturitas; 2014 Sep; 79(1):48-51. PubMed ID: 25086726
[TBL] [Abstract][Full Text] [Related]
3. Nanoparticle delivery of siRNA against TWIST to reduce drug resistance and tumor growth in ovarian cancer models.
Roberts CM; Shahin SA; Wen W; Finlay JB; Dong J; Wang R; Dellinger TH; Zink JI; Tamanoi F; Glackin CA
Nanomedicine; 2017 Apr; 13(3):965-976. PubMed ID: 27890656
[TBL] [Abstract][Full Text] [Related]
4. RNA-based TWIST1 inhibition via dendrimer complex to reduce breast cancer cell metastasis.
Finlay J; Roberts CM; Lowe G; Loeza J; Rossi JJ; Glackin CA
Biomed Res Int; 2015; 2015():382745. PubMed ID: 25759817
[TBL] [Abstract][Full Text] [Related]
5. Circulating Tumor Cells with Stemness and Epithelial-to-Mesenchymal Transition Features Are Chemoresistant and Predictive of Poor Outcome in Metastatic Breast Cancer.
Papadaki MA; Stoupis G; Theodoropoulos PA; Mavroudis D; Georgoulias V; Agelaki S
Mol Cancer Ther; 2019 Feb; 18(2):437-447. PubMed ID: 30401696
[TBL] [Abstract][Full Text] [Related]
6. Establishment of Acquired Cisplatin Resistance in Ovarian Cancer Cell Lines Characterized by Enriched Metastatic Properties with Increased Twist Expression.
Bahar E; Kim JY; Kim HS; Yoon H
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33076245
[TBL] [Abstract][Full Text] [Related]
7. Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer.
Shahin SA; Wang R; Simargi SI; Contreras A; Parra Echavarria L; Qu L; Wen W; Dellinger T; Unternaehrer J; Tamanoi F; Zink JI; Glackin CA
Nanomedicine; 2018 Jun; 14(4):1381-1394. PubMed ID: 29665439
[TBL] [Abstract][Full Text] [Related]
8. The DNA Damage Transducer RNF8 Facilitates Cancer Chemoresistance and Progression through Twist Activation.
Lee HJ; Li CF; Ruan D; Powers S; Thompson PA; Frohman MA; Chan CH
Mol Cell; 2016 Sep; 63(6):1021-33. PubMed ID: 27618486
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile.
Latifi A; Abubaker K; Castrechini N; Ward AC; Liongue C; Dobill F; Kumar J; Thompson EW; Quinn MA; Findlay JK; Ahmed N
J Cell Biochem; 2011 Oct; 112(10):2850-64. PubMed ID: 21618587
[TBL] [Abstract][Full Text] [Related]
10. Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer.
Deng J; Wang L; Chen H; Hao J; Ni J; Chang L; Duan W; Graham P; Li Y
Oncotarget; 2016 Aug; 7(34):55771-55788. PubMed ID: 27304054
[TBL] [Abstract][Full Text] [Related]
11. Exosome-sheathed porous silica nanoparticle-mediated co-delivery of 3,3'-diindolylmethane and doxorubicin attenuates cancer stem cell-driven EMT in triple negative breast cancer.
Sarkar R; Biswas S; Ghosh R; Samanta P; Pakhira S; Mondal M; Dutta Gupta Y; Bhandary S; Saha P; Bhowmik A; Hajra S
J Nanobiotechnology; 2024 May; 22(1):285. PubMed ID: 38796426
[TBL] [Abstract][Full Text] [Related]
12. Garcinol sensitizes breast cancer cells to Taxol through the suppression of caspase-3/iPLA
Tu SH; Chiou YS; Kalyanam N; Ho CT; Chen LC; Pan MH
Food Funct; 2017 Mar; 8(3):1067-1079. PubMed ID: 28145547
[TBL] [Abstract][Full Text] [Related]
13. Silencing β3 Integrin by Targeted ECO/siRNA Nanoparticles Inhibits EMT and Metastasis of Triple-Negative Breast Cancer.
Parvani JG; Gujrati MD; Mack MA; Schiemann WP; Lu ZR
Cancer Res; 2015 Jun; 75(11):2316-2325. PubMed ID: 25858145
[TBL] [Abstract][Full Text] [Related]
14. Blocking Stemness and Metastatic Properties of Ovarian Cancer Cells by Targeting p70
Ma J; Kala S; Yung S; Chan TM; Cao Y; Jiang Y; Liu X; Giorgio S; Peng L; Wong AST
Mol Ther; 2018 Jan; 26(1):70-83. PubMed ID: 29241971
[TBL] [Abstract][Full Text] [Related]
15. Twist-BRD4 complex: potential drug target for basal-like breast cancer.
Shi J; Cao J; Zhou BP
Curr Pharm Des; 2015; 21(10):1256-61. PubMed ID: 25506891
[TBL] [Abstract][Full Text] [Related]
16. Epithelial-mesenchymal transition and cancer stem cell-like phenotype induced by Twist1 contribute to acquired resistance to irinotecan in colon cancer.
Yang Y; Wang G; Zhu D; Huang Y; Luo Y; Su P; Chen X; Wang Q
Int J Oncol; 2017 Aug; 51(2):515-524. PubMed ID: 28627611
[TBL] [Abstract][Full Text] [Related]
17. Pomegranate Extract Alters Breast Cancer Stem Cell Properties in Association with Inhibition of Epithelial-to-Mesenchymal Transition.
Nallanthighal S; Elmaliki KM; Reliene R
Nutr Cancer; 2017 Oct; 69(7):1088-1098. PubMed ID: 28976208
[TBL] [Abstract][Full Text] [Related]
18. SPZ1 is critical for chemoresistance and aggressiveness in drug-resistant breast cancer cells.
Liu X; Han X; Wan X; He C; Wang Y; Mao A; Yu F; Zhou T; Feng L; Zhang P; Jin J; Ma X
Biochem Pharmacol; 2018 Oct; 156():43-51. PubMed ID: 30076850
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of TWIST enhances the cytotoxicity of chemotherapeutic drugs in doxorubicin-resistant HepG2 cells by suppressing MDR1 and EMT.
Li R; Wu C; Liang H; Zhao Y; Lin C; Zhang X; Ye C
Int J Oncol; 2018 Oct; 53(4):1763-1773. PubMed ID: 30066890
[TBL] [Abstract][Full Text] [Related]
20. Twist: a molecular target in cancer therapeutics.
Khan MA; Chen HC; Zhang D; Fu J
Tumour Biol; 2013 Oct; 34(5):2497-506. PubMed ID: 23873099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
